JP2020189879A5 - - Google Patents

Download PDF

Info

Publication number
JP2020189879A5
JP2020189879A5 JP2020139045A JP2020139045A JP2020189879A5 JP 2020189879 A5 JP2020189879 A5 JP 2020189879A5 JP 2020139045 A JP2020139045 A JP 2020139045A JP 2020139045 A JP2020139045 A JP 2020139045A JP 2020189879 A5 JP2020189879 A5 JP 2020189879A5
Authority
JP
Japan
Prior art keywords
fibrosis
disease
antagonist
liver
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020139045A
Other languages
English (en)
Japanese (ja)
Other versions
JP7102474B2 (ja
JP2020189879A (ja
Filing date
Publication date
Priority claimed from GBGB1522186.4A external-priority patent/GB201522186D0/en
Application filed filed Critical
Publication of JP2020189879A publication Critical patent/JP2020189879A/ja
Publication of JP2020189879A5 publication Critical patent/JP2020189879A5/ja
Application granted granted Critical
Publication of JP7102474B2 publication Critical patent/JP7102474B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020139045A 2015-12-16 2020-08-20 線維化の治療 Active JP7102474B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522186.4A GB201522186D0 (en) 2015-12-16 2015-12-16 Treatment of fibrosis
GB1522186.4 2015-12-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018531325A Division JP6753933B2 (ja) 2015-12-16 2016-12-16 線維化の治療

Publications (3)

Publication Number Publication Date
JP2020189879A JP2020189879A (ja) 2020-11-26
JP2020189879A5 true JP2020189879A5 (https=) 2021-03-11
JP7102474B2 JP7102474B2 (ja) 2022-07-19

Family

ID=55274842

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018531325A Active JP6753933B2 (ja) 2015-12-16 2016-12-16 線維化の治療
JP2020139045A Active JP7102474B2 (ja) 2015-12-16 2020-08-20 線維化の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018531325A Active JP6753933B2 (ja) 2015-12-16 2016-12-16 線維化の治療

Country Status (24)

Country Link
US (16) US10035852B2 (https=)
EP (7) EP3428187A1 (https=)
JP (2) JP6753933B2 (https=)
KR (2) KR20240152973A (https=)
CN (2) CN116036284A (https=)
AU (7) AU2016369407B2 (https=)
CA (1) CA3007750A1 (https=)
CY (1) CY1120950T1 (https=)
DK (1) DK3298040T3 (https=)
ES (1) ES2692773T3 (https=)
GB (1) GB201522186D0 (https=)
HR (1) HRP20181692T1 (https=)
HU (1) HUE041433T2 (https=)
LT (1) LT3298040T (https=)
NZ (1) NZ744307A (https=)
PL (1) PL3298040T3 (https=)
PT (1) PT3298040T (https=)
RS (1) RS57894B1 (https=)
SG (2) SG10201908380TA (https=)
SI (1) SI3298040T1 (https=)
SM (1) SMT201800601T1 (https=)
TR (1) TR201815415T4 (https=)
WO (1) WO2017103108A1 (https=)
ZA (1) ZA201803727B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
US20180186871A1 (en) * 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201621439D0 (en) * 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
EP3914621A1 (en) 2019-01-21 2021-12-01 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
GB201902419D0 (en) * 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
BR112021021921A2 (pt) * 2019-05-03 2021-12-28 Nat Univ Singapore Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
US12343336B2 (en) 2019-08-05 2025-07-01 Novocure Gmbh Increasing cancer cells' sensitivity to tumor treating fields (TTFields) by inhibiting IL11 activity
KR102270700B1 (ko) * 2019-11-01 2021-06-30 한국과학기술연구원 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
EP4198055A4 (en) * 2020-08-13 2024-08-28 Sunshine Lake Pharma Co., Ltd. IL-11 ANTIBODY AND ITS USE
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
JP2024512279A (ja) 2021-02-26 2024-03-19 バイエル アクチェンゲゼルシャフト 異常子宮出血の処置における使用のためのil-11又はil-11raの阻害剤
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
MX2024002611A (es) 2021-08-30 2024-05-29 Lassen Therapeutics 1 Inc Anticuerpos anti-il-11ra.
CN115068442A (zh) * 2021-09-13 2022-09-20 荣灿生物医药技术(上海)有限公司 核酸的纳米颗粒组合物、其制备方法和用途
US20250082608A1 (en) 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
CN115414346B (zh) * 2022-08-29 2023-09-29 湖南复瑞生物医药技术有限责任公司 一种应用胺碘酮构造肺纤维化模型的方法
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
EP4702047A1 (en) 2023-04-25 2026-03-04 VVB Bio Pte. Ltd. Anti il-11 antibody
CN120518761B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种结合il-11的抗体、其抗原结合片段及应用
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
CN117085137A (zh) * 2023-10-10 2023-11-21 上海交通大学医学院附属第九人民医院 Il-11抑制剂及其在抗瘢痕治疗中的应用
CN117964734B (zh) * 2024-03-04 2025-12-26 四川大学 一种重组人白介素-11突变体及其与化学分子偶联缀合物和其制备方法与应用
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
EP1566440A3 (en) 1994-12-22 2005-10-19 Genetics Institute, Inc. Human Interleukin-11 Receptor
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5679339A (en) 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
GB9721961D0 (en) 1997-10-16 1997-12-17 Glaxo Group Ltd Novel molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
WO2000078336A1 (en) * 1999-06-21 2000-12-28 Genetics Institute, Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
GB0021668D0 (en) 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
WO2003049693A2 (en) 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
WO2004024125A1 (en) 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
JP2007537716A (ja) 2003-12-16 2007-12-27 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション サイトカイン結合ドメイン
EP1720562A4 (en) 2004-01-15 2009-10-28 Scios Inc METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE
WO2005098041A2 (en) 2004-03-26 2005-10-20 University Of Florida Research Foundation, Inc. Detection and treatment of fibrotic disorders
ATE399868T1 (de) 2004-08-27 2008-07-15 Conaris Res Inst Ag Optimierte nukleotidsequenzen die für sgp130 kodieren
EP1957097A1 (en) 2005-12-06 2008-08-20 Wyeth a Corporation of the State of Delaware Interleukin-11 compositions and methods of use
MX352516B (es) 2006-07-05 2017-04-06 Fibrotech Therapeutics Pty Ltd Compuestos terapeuticos.
JP5191393B2 (ja) * 2006-10-27 2013-05-08 国立大学法人大阪大学 インターロイキン11の心疾患治療薬としての利用
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US8182814B2 (en) * 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
JP5330398B2 (ja) 2007-10-26 2013-10-30 シーエスエル、リミテッド サイトカインムテイン
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
CN117843785A (zh) * 2013-02-07 2024-04-09 Csl有限公司 Il-11r结合蛋白及其应用
CN105497893B (zh) 2015-12-10 2019-02-01 黑龙江省科学院高技术研究院 IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
RU2016151730A (ru) 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11
GB201716733D0 (en) 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
NL2020093B1 (en) 2017-12-15 2019-06-25 Stahl Int B V Process for producing aqueous polyurethane dispersions in a continuous manner; apparatus suitable for performing such a process; and products obtained by said process
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Similar Documents

Publication Publication Date Title
JP2020189879A5 (https=)
CN103443098B (zh) 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用
JP2020511414A5 (https=)
JP2020513745A5 (https=)
JP2017505784A5 (https=)
JP2009531036A5 (https=)
JP2017520527A5 (https=)
JP2011201916A5 (https=)
JP2015520130A5 (https=)
JP2022527270A5 (https=)
JP2014500280A5 (https=)
WO2018183795A1 (en) Method of making tetrahydronaphthyridinyl nonanoic acid compounds
CN109761958B (zh) 法舒地尔复合盐及其制备方法和用途
JP6099209B2 (ja) 黄斑変性の予防または治療用の医薬組成物
JP2019508184A5 (https=)
RS50129B (sr) Optički aktivan derivat piridil-4h-1,2,4-oksadiazina i njegova upotreba u proizvodnji lekova za tretiranje vaskularnih bolesti
JP4938928B2 (ja) ピリダジノン誘導体の新規用途
CN1111631A (zh) 含3-苯磺酰基-3,7-二氮杂双环[3,3,1]壬烷的药物
CN106661060B (zh) 菲罗啉膦酸类衍生物及其制备方法和应用
JP5583028B2 (ja) オキサゾリジン及びチアゾリジン選択的サブタイプアルファ2アドレナリン作用薬並びにこれらの使用方法
CN109966243A (zh) 一种用于眼底黄斑治疗的释药型凝胶及其制备方法
RU2013130023A (ru) Новые производные пиридина в качестве модуляторов рецептора сфингозин 1-фосфата (s1p)
JP2024530888A5 (https=)
JP5480819B2 (ja) 選択的サブタイプアルファ2アドレナリンアゴニスト及びその使用方法
CN106474113B (zh) 一种用于缺血性脑卒中后神经再生的药物组合物及其应用